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Presentación 
Los tumores del estroma gastrointestinal, conocidos como GIST (por sus siglas en inglés, 
Gastrointestinal Stromal Tumors), son los tumores mesenquimales más frecuentes del tracto 
digestivo, y se han convertido en un paradigma importante en oncología traslacional, ejemplificando 
mejor que cualquier otro tumor sólido el impacto que la investigación básica puede tener en el 
desarrollo racional de fármacos. En tan solo una década, la investigación traslacional aplicada al GIST 
ha permitido desarrollar hasta tres líneas terapéuticas de aplicación secuencial, culminando un 
proceso de desarrollo farmacológico racional sin precedentes. En la actualidad, existen tres fármacos 
dirigidos contra dianas terapéuticas específicas en GIST, que son eficaces y han sido aprobados para 
su tratamiento; estos fármacos han ampliado notablemente la calidad y la esperanza de vida de estos 
pacientes oncológicos. 
Los GIST se originan por mutaciones activadoras en el oncogén KIT, un receptor tirosina 
quinasa cuya activación constitutiva es esencial para la proliferación y la supervivencia de las células 
tumorales. Este tumor es, por tanto, un modelo de la llamada adicción oncogénica, en el que la 
viabilidad de las células tumorales depende específicamente de la acción de un oncogén principal. 
Las versiones mutantes más frecuentes de KIT (con alteraciones en el exón 11 o en el exón 9) pueden 
ser bloqueadas por el fármaco inhibidor de tirosina quinasa imatinib (Glivec®). Este fármaco es 
enormemente eficaz en la mayoría de los pacientes, incluso aplicado en monoterapia, y consigue 
controlar la enfermedad durante 18-24 meses en pacientes en los que una resección quirúrgica con 
intención curativa no es posible. Muchos de los avances conseguidos con el estudio del bloqueo de 
KIT en GIST han permitido un avance importante en el tratamiento de otras neoplasias –como la 
leucemia mieloide crónica, o algunos subtipos de melanoma y de cáncer de pulmón- por lo que se 
considera un modelo contrastado y válido no solo para la investigación en sarcomas, sino también 
para otros tipos de cáncer. Además, debido a la especificidad del fármaco hacia su diana terapéutica, 
este tumor se considera un ejemplo prototípico de la llamada medicina de precisión en oncología, 
comparable al carcinoma de mama con amplificación de HER-2. 
A pesar de los grandes avances en el tratamiento del GIST con imatinib, y las sucesivas líneas 
terapéuticas – sunitinib (Sutent ®) y regorafenib (Stivarga®) – el 90% de los pacientes desarrollan 
resistencia al tratamiento tras unos 2 años de respuesta clínica. Aunque se conocen algunos de los 
mecanismos de resistencia, que consisten principalmente en mutaciones secundarias en regiones 
concretas del gen, todavía se desconocen muchos de ellos y la forma de contrarrestarlos. El estudio 
de estos mecanismos de resistencia a terapias dirigidas en GIST es un área de investigación de gran 
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interés actualmente. El otro gran campo de interés es el desarrollo de nuevos fármacos dirigidos, con 
mecanismos de acción distintos a los inhibidores de tirosina quinasa pero complementarios a ellos, 
que permitan maximizar la respuesta y que, presumiblemente, no se verán afectados por los mismos 
mecanismos de resistencia. 
El desarrollo de fármacos en la oncología contemporánea se realiza mediante un proceso de 
diseño racional, basado en la caracterización exhaustiva de los mecanismos moleculares que rigen la 
biología tumoral para descubrir vulnerabilidades específicas que puedan ser explotadas 
terapéuticamente. En este campo, las técnicas moleculares de alto rendimiento están revolucionado 
la investigación biomédica, al acelerar radicalmente el ritmo de descubrimiento de los mecanismos 
oncogénicos. A raíz de los importantes avances tecnológicos que han acompañado al desarrollo de 
las llamadas tecnologías de secuenciación masiva, en la actualidad es posible analizar 
simultáneamente gran cantidad de parámetros biológicos en paralelo, de forma más eficiente que los 
experimentos tradicionales, en los que cada parámetro debía analizarse por separado. Diversos 
diseños experimentales utilizando este tipo de técnicas permiten contrastar miles de hipótesis en un 
solo experimento, de forma objetiva y no sesgada, generando gran volumen de datos a una velocidad 
sin precedentes. Los primeros estudios utilizando estas tecnologías han generado resultados muy 
prometedores en campos tan diversos como el de las enfermedades infecciosas –v.g. interacciones 
patógeno-huésped en los virus de la gripe o el VIH–, las enfermedades neurodegenerativas –
mecanismos patogénicos en enfermedad de Alzheimer– y, especialmente, el de la oncología –
neoplasias hematológicas, melanoma, cáncer de pulmón, y cáncer de ovario, entre otros. Las librerías 
funcionales a escala genómica son técnicas de alto rendimiento validadas recientemente, ya sea 
utilizando RNA de interferencia (para análisis de pérdida de función) o vectores de expresión 
(“ORFs”, para estudio de aumento de función). La característica diferencial de estos experimentos es 
que generan información funcional, informan de qué hacen los genes – en contraposición a la 
información estructural de las técnicas preexistentes, que informan sobre cómo son los genes – y 
aportan información más “cercana al fenotipo” y, por tanto, más directamente relacionada con la 
biología tumoral. En los formatos disponibles actualmente, estas librerías permiten estudiar 
simultáneamente la importancia relativa de más de 18000 genes (el genoma completo). 
En este contexto se enmarca el proyecto de investigación presenstado aquí. Tratamos de 
identificar los mecanismos moleculares esenciales para la supervivencia y proliferación de las células 
tumorales, para identificar vulnerabilidades que puedan ser utilizadas como nuevas dianas 
terapéuticas, mediante el estudio funcional de todo el genoma en modelos celulares de GIST, 
utilizando librerías de shRNA.  
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Resumen 
El objectivo principal de este proyecto de investigación es el desarrollo de nuevas estrategias 
terapéuticas que permitan controlar la resistencia a inhibidores de tirosina quinasa y que prolonguen 
la supervivencia global de los pacientes con GIST. Mediante el uso de tecnologías de última 
generación y modelos celulares representativos, queremos descubrir nuevas dianas terapéuticas en 
las células de GIST mediante el estudio sistemático de las alteraciones que subyacen la iniciación y 
progresión tumoral, y el desarrollo de resistencia terapéutica. Para conseguirlo, hemos desarrollado 
un plan de trabajo para establecer tecnologías de screening de alto rendimiento en el laboratorio del 
Profesor Jonathan Fletcher, en el Hospital Brigham and Women’s, en colaboración con la Pataforma 
de Perturbaciones Genéticas del Broad Institute, ambos situados en Boston, Massachusetts. 
Durante los últimos 5 años, hemos desarrollado las técnicas experimentales necesarias para 
interrogar de forma sistemática la función de todo el genoma en células de GIST. Hemos completado 
prevalidaciones, screening y experimentos de validación con dos líneas celulares de GIST con 
mutaciones de KIT, y hemos validado con éxito una nueva diana terapéutica, CDC37, una 
cochaperona de HSP90. Además hemos establecido una plataforma genómica funcional para el 
estudio sistemático de células de sarcoma, que nos permite examinar múltiples histotipos para 
descubrir vulnerabilidades específicas de cada tipo, así como vulnerabilidades biológicas compartidas 
entre diversos sarcomas. 
Triangulando información genómica funcional generada mediante estos experimentos, con 
datos complementarios –como perfiles mutacionales, perfiles de expresión génica, o screenings 
químicos y farmacológicos–  podremos desarrollar nuevas estrategias terapéuticas y maximizar el 
beneficio clínico obtenido por los pacientes afectados por estos tumores. 
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Summary 
Gastrointestinal stromal tumors (GIST) are the epitome of clinically effective targeted 
inhibition of oncogenic driver mutations, and serve as a rational clinical model to evaluate 
mechanisms of oncogenic progression, new molecularly-targeted therapies, and mechanisms for drug 
response and resistance. Uninterrupted translational research efforts have led to the development of 
highly effective targeted agents which are now available to treat GIST patients and induce remarkable 
clinical responses. The major challenge we face at present is the emergence of secondary drug 
resistance, which stems from the morphologic and genetic complexity of the disease, before and after 
treatment with targeted agents, hindering long-term disease control. 
The main goal of this research project is to design novel therapeutic strategies that will extend 
the long-term survival of GIST patients by overcoming TKI-resistance. Utilizing state-of-the-art 
technologies and biologically representative cellular models, we aim to identify targetable 
vulnerabilities in GIST cells by systematically characterizing the molecular deregulations that 
underlie GIST development, tumor progression, and development of resistance to pharmacologic 
inhibitors. To this end, we designed a hypothesis-driven study plan using a set of high-throughput 
genetic screening efforts at the laboratory of Professor Jonathan Fletcher, at Brigham and Women’s 
Hospital, in collaboration with the Genetic Perturbations Platform at the Broad Institute, both located 
in Boston, MA, USA. 
Over the past five years I have developed experimental approaches for comprehensive genome 
wide functional characterizations in GIST cells. We have completed the required prevalidations, 
screening, and follow-up experiments for 2 KIT mutant GIST cell lines, and we have successfully 
validated a potential therapeutic target in GIST, the HSP90 cochaperone CDC37. Furthermore, we 
have established a functional genomics-based discovery pipeline applicable to sarcoma cells that 
allows us to screen multiple sarcoma types to discover type-specific biologic vulnerabilities, in 
addition to shared biological themes. Triangulation of functional genomic data with orthogonal 
datasets –such as mutational profiles, copy number data, transcriptome and chemical screens- will 
allow us to design novel therapeutic strategies to maximize clinical benefit for patients affected by 
these devastating tumors. 
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Introduction 
Gastrointestinal Stromal Tumor (GIST) 
Basic epidemiology and clinicopathological features 
GIST is the most common mesenchymal tumor of the gastrointestinal tract. Despite their 
relatively low frequency as a clinical problem, subclinical forms of GIST are much more common 
than traditionally appreciated [Kawanowa et al., 2006; Agaimy et al., 2007], and may be detected 
incidentally after surgical resections for unrelated diseases, or during autopsy [Agaimy et al., 2008]. 
Microscopic GIST (measuring <1 cm) are observed in up to 35% of gastroesophageal resections; so-
called minute sclerosing GIST (<5 mm) can be grossly detected in the proximal stomach in ~20% of 
autopsies of patients older than 50 years [Agaimy et al., 2008]. Only a small fraction of these lesions 
will progress to cause clinical manifestations, reaching an annual incidence of around 11-15 per 
100,000 people [Nilsson et al., 2005]. A major unresolved question is the series of events that allow 
for these preclinical lesions to progress to a malignant GIST, and understanding these steps may 
provide opportunities for strategic therapeutic intervention. 
GIST typically affects older adults, manifesting at a median age of 60-65 years with no gender 
predilection. The most common anatomic location is the stomach (60%), followed by the small 
intestine, rectum, esophagus, omentum, and mesentery [Miettinen and Lasota, 2001; Miettinen and 
Lasota, 2006]. So-called extragastrointestinal GIST comprise tumors primarily detected in the 
omentum or mesentery in which an organ of origin cannot be determined. Exceptional cases are 
described in other locations [Long et al., 2010] and may represent unusually indolent metastases from 
unrecognized primary tumors. The clinical presentation of GIST is rather non-specific, just related to 
the mass effect at the anatomic location of the tumor; submucosal lesions often cause acute 
gastrointestinal bleeding due to ulceration of overlying mucosa [Miettinen and Lasota, 2001; Fletcher 
et al., 2002]. Lymph node metastases are very rare and are suggestive of a particular molecular type 
of GIST, which is SDH-deficient [Doyle et al., 2012]. 
Grossly, GIST typically present as sharply demarcated tumors, showing frequently a 
submucosal growth (Figure 1). The presence of multiple distinct tumors may represent multiple 
primary tumors, but most often represents local or regional metastases to the GI tract [Corless et al., 
2004; Gasparotto et al., 2008]. Multiple GIST are occasionally syndromic: GIST can be an expression 
of several rare clinical syndromes in which patients are affected by multiple mesenchymal tumors, 
such as neurofibromatosis type 1, familial GIST, Carney-Stratakis syndrome, and Carney triad 
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[Nishida et al., 1998; Carney and Stratakis, 2002; Miettinen et al., 2006; Stratakis and Carney, 2009; 
Janeway et al., 2011]. Syndromic presentations are much less frequent than sporadic GIST (<10% of 
cases), and are clinically recognizable due to particular associations. Their main relevance is that they 
have provided invaluable insights into the biology of the disease, pinpointing to specific genetic 
alterations that contribute to GIST pathogenesis.  
Histologically, GIST may be composed of spindle or epithelioid cells, or show mixed 
cytomorphology (70, 20 and 10% of cases, respectively) (Figure 2) [Corless et al., 2004]. 
Phenotype/genotype associations regarding cytomorphology are not specific enough to be clinically 
useful, the strongest ones being the association of epithelioid morphology and gastric location with 
PDGFRA mutation, and small bowel spindle cell GIST associated with neurofibromatosis. Rare 
morphologic appearances include cellular pleomorphism, and palisading, trabecular/endocrine, 
insular/epithelial, lacunar, chondroid, angiomatous or rhabdoid morphology, with no consistent 
clinical significance [Liegl et al., 2009a; Liegl-Atzwanger et al., 2010; Miettinen and Lasota, 2013; 
Schaefer et al., 2014b]. A distinctive multinodular or plexiform growth pattern is observed in SDH-
deficient GIST, in which discrete nodules of tumor cells are separated by bands of pre-existing 
Figure 1: GIST morphology. Macrocopically, this lesion is a 3.5 fleshy solid mass with central necrosis and hemorrhage, 
located in the submucosa of the gastric wall (A). Histologically, the tumor consists in a homogeneous proliferation of 
short spindle cells (B) with syncytial palely eosinophilic cytoplasm, slightly fibrillary in appeareance, and ovoid nuclei 
with regular contours and homogeneous chromatin (C). Perinuclear vacuolization is commong in spindle cell GIST (D).  
About 20% of GIST show predominantly epithelioid morphology, tipically in gastric location (E). KIT expression, 
usually diffusely and strong, is readily detectable by immunohistochemistry in more than 95% of GIST. 
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smooth muscle, with small satellite tumor nodules [Rege et al., 2011; Doyle et al., 2012]. 
Immunohistochemically, GIST express KIT (CD117) in 95% of cases, DOG-1 in 98%, platelet-
derived growth factor receptor-alpha (PDGFRA) in 80%, and CD34 in 70-80% [Medeiros et al., 
2004; Miettinen et al., 2009; Liegl et al., 2009b; Liegl-Atzwanger et al., 2010]. The majority of GIST 
show a strong and diffuse cytoplasmic KIT staining, with a concurrent paranuclear dot (“Golgi”) 
pattern in almost half of the cases [Hornick and Fletcher, 2007; Tabone-Eglinger et al., 2008]. The 
small subset of GIST that do not express KIT oncoprotein (4-5% of cases) are more likely to have 
epithelioid cell morphology, contain PDGFRA oncogenic mutations, and arise in the 
omentum/peritoneal surface or the stomach. Notably, most KIT-negative GIST still contain imatinib-
sensitive KIT or PDGFRA mutations, and similar cytogenetic profiles. Loss of normal SDHB and 
SDHA expression can be detected by immunohistochemistry to identify SDH-deficient GIST. GIST 
also express proteins indicative of a partial myogenic phenotype, including smooth muscle actin 
(SMA) and H-caldesmon, both present in 50-60% of cases. Desmin, however, is expressed very 
rarely, in less than 5% of cases (although there is substantial variation amongst the series reported) 
[Miettinen et al., 1999; Novelli et al., 2010]. So-called dedifferentiated GIST represent an 
exceptionally rare form of progression to a high-grade sarcoma which is by definition unrecognizable 
histologically in the absence of residual typical areas [Antonescu et al., 2013].  
Approximately 30% of GIST are malignant, and develop local recurrence or distant 
metastases. The biologic potential of GIST is difficult to ascertain at time of diagnosis, based solely 
on conventional histologic criteria; the definition of malignancy is hence based on a risk estimation 
system. Risk determination relies on several criteria, such as tumor size, tumor site and mitotic index, 
which are scored according to risk assessment scales that have been incrementally refined in large 
series of cases. One of the most widely accepted system is the National Comprehensive Cancer 
Network (NCCN) criteria from 2007 [Demetri et al., 2007], which has been extensively validated for 
KIT and PDGFRA mutant GIST. The improved understanding of GIST biology and the continuous 
development of therapeutic agents with activity against specific mutations highlights the importance 
of mutational analysis of these tumors, which will likely be incorporated into future risk-stratification 
systems. 
Molecular pathology and oncogenic signaling 
The prototypical oncogenic driver of GIST is the receptor tyrosine kinase KIT, which is 
constitutively active due to gain-of-function mutations in ~70-80% of cases [Corless et al., 2004]. An 
additional ~10% of GIST are driven by activating mutations in the analogous receptor kinase 
PDGFRA. PDGFRA-driven GIST show a predilection for gastric location and an epithelioid 
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phenotype [Heinrich et al., 2003b; 
Wardelmann et al., 2004; Corless et 
al., 2005]. KIT and PDGFRA 
mutations lead to ligand-independent 
activation of these receptors, which 
activates intracellular signaling 
pathways controlling cell 
proliferation, adhesion, apoptosis, 
survival, and differentiation 
[Duensing et al., 2004b]. KIT primary 
mutations usually affect exon 11 
(70%), exon 9 (10%), exon 13 (1%) or 
exon 17 (1%), whereas PDGFRA 
mutations affect exon 18 (5%), 12 
(1%) or 14 (<1%) [Corless et al., 
2004].  
The pattern and level of KIT expression do not correlate with the underlying mutation, 
although PDGFRA-mutants often show weaker KIT expression [Medeiros et al., 2004]. KIT 
mutations in GIST not only induce receptor auto activation, but also an activation-dependent 
alteration of normal protein maturation and trafficking, resulting in the intracellular retention of the 
activated kinase within the cell; as a result, mutated KIT alleles are mainly expressed as an immature 
phosphorylated protein within the intracellular compartments rather than at the cell surface [Tabone-
Eglinger et al., 2008]. This situation is strikingly different in other RTK-driven tumors, like HER2-
positive breast ductal carcinoma, in which HER2 receptors are readily accessible to blocking 
antibodies that bind to extracellular domains of the oncoprotein, like trastuzumab. The efficacy of 
similar therapeutic strategies in GIST may be limited, although recent experiments using anti-KIT 
monoclonal antibodies have shown promising results [Edris et al., 2013]. It has also been proposed 
that this mechanism of cytoplasmic retention may explain the lack of correlation between imatinib 
response and KIT expression [Tabone-Eglinger et al., 2008].  
The three major signaling pathways activated by constitutive KIT and PDGFRA activation 
are 1) the PI3K/AKT/mTOR pathway, 2) the RAS/RAF/MAPK pathway, and 3) the JAK/STAT 
pathway [Duensing et al., 2004b; Bauer et al., 2007]. The latter pathway is known to be relevant in 
mast cell disease harboring KIT mutations but plays only a limited role in GIST. The 
Figure 2: KIT mutations in untreated GISTs involve exons 11, 9, 13, 
and 17, encoding parts of the extracellular, juxtamembrane, ATP-
binding pocket, and activation loop domains, respectively. PDGFRA 
mutations, found in <10% of GISTs, involve analogous domains. 
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PI3K/AKT/mTOR and the RAS/RAF/MAPK pathways, on the other hand, are crucial for 
proliferation in GIST and offer potential therapeutic targets [Floris et al., 2013; Patel, 2013]. To 
engage these downstream signaling pathways, activation of KIT is followed by binding of the adaptor 
protein complexes SHC, GRB2 and SOS, which transduce and amplify the signal. Downstream 
dependency on these two pathways is comparable to that well documented in other tumor types, such 
as glioblastoma [Cancer Genome Atlas Research Network, 2008], uveal melanoma [Khalili et al., 
2012] and non-small cell lung carcinoma [Sos et al., 2009]; GIST provides a unique opportunity to 
explore combination therapy approaches targeting these critical pathways, given its much simpler 
genomic context and the excellent cellular models available.  
Hyperactivation of the PI3K/AKT/mTOR pathway is central to oncogenic signaling in GIST 
and possibly related to imatinib-resistance, thus offering potential targets for combinatorial 
therapeutic strategies [Bauer et al., 2007; Patel, 2013; Floris et al., 2013]. AKT phosphorylation 
through PI3K results in increased protein translation, downregulation of the cell cycle inhibitor p27, 
and anti-apoptotic effects through mTOR and p70S6K [Corless et al., 2011]. PTEN functions as a 
negative regulator of this signaling pathway. Both PIK3CA mutations and PTEN deletions have been 
documented in KIT-mutant GIST, probably contributing increased flux through this signaling 
pathway [Yang et al., 2012; Quattrone et al., 2014]. A loss or decrease of PTEN expression is 
observed during GIST progression, and PTEN status in GIST might be used as a possible surrogate 
predictive biomarker of response to PI3K inhibitors in GIST [Ricci et al., 2004]. Protein kinase C  
(PKC), part of the PI3K/AKT/mTOR pathway, is a useful biomarker in GIST given its narrow range 
of expression in normal cells, including the interstitial cells of Cajal [Duensing et al., 2004a; Zhu et 
al., 2007]. PKC is phosphorylated in a KIT-dependent manner, either by PI3K or KIT itself, 
suggesting that KIT and PKCθ participate in a positive feedback loop in GIST [Ou et al., 2008]. 
PKCθ expression and activation are crucial to GIST cell survival and proliferation regulating KIT 
expression, cell proliferation, and cell survival. Thus, PKC offers an additional potential therapeutic 
target in GIST, including imatinib-resistant tumors.  
Activation of RAS and the downstream MAPK cascade – RAF, MEK, and ERK – ultimately 
results in changes in gene expression through MYC and ELK1. The activation of p90RSK by ERK 
increases the activity of several oncogenic transcription factors, and downregulates CIC, which is a 
transcriptional suppressor of ETV1 [Corless et al., 2011]. Through this signaling cascade, activated 
KIT ultimately induces the transcription of ETV1, prolongs ETV1 protein stability and cooperates 
with ETV1 in tumorigenesis. The transcription factor ETV1 is a member of the ETS family that 
regulates the lineage-specific gene expression program characteristic of interstitial cells of Cajal and 
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GIST, in which it is highly expressed and plays an important role in cell growth and survival [Chi et 
al., 2010].  
A small subset of GIST are wild-type for KIT and PDGFRA, and are frequently designated 
“wild-type GIST”. Most of these demonstrate mutations in genes like NF-1, BRAF or any of the three 
canonical RAS gene family members, which lead to activation of the RAS/MAPK pathway and add 
up to 10% of cases [Serrano et al., 2014] (Publication II). An even smaller subset, ~5% of all GIST, 
demonstrate decreased expression of subunits of the SDH mitochondrial complex, most often due to 
loss-of-function mutations, and are grouped under the designation “SDH-deficient GIST” [Janeway 
et al., 2011]. Finally, about 2% of GIST do not demonstrate mutations in any of the known potential 
driver genes and express normal levels of all SDH subunits, lacking an identifiable genetic driver. 
The degree of biologic overlap between different molecular subtypes of GIST is variable. In contrast 
with the tremendous progress in our understanding of KIT-mutant GIST, research in other molecular 
types is hindered by the lack of appropriate laboratory models. 
Molecular mechanisms of tumor progression 
GIST originate from interstitial cells of Cajal (ICC) or their precursors. A model of 
progression can be devised in which the initiating oncogenic event, most often a gain-of-function 
mutation of KIT or PDGFRA, results in increased proliferation that sequentially leads to ICC 
hyperplasia, microscopic GIST, clinical localized GIST, and metastatic GIST – ultimately followed 
by TKI-resistant GIST, if the patient receives TKI treatment. Such a progression model, comparable 
to the adenoma-carcinoma sequence that underlies epithelial neoplasia, sets GIST apart from most 
types of sarcomas, in which a precancerous lesion has not been identified. Key genetic events along 
this neoplastic sequence have been elucidated. The discrepancy in frequency between microscopic 
and clinical GIST indicates that GIST oncogenic progression can be arrested at several stages, so that 
early tumors present in up to 30% of the population regularly fail to acquire the genetic hits required 
to fully progress to malignancy. 
KIT and PDGFRA mutations are initiating events in GIST tumorigenesis, but do not 
necessarily lead to further genetic progression or aggressive behavior; these aberrations can be found 
in indolent lesions such as incidental microscopic GIST [Corless et al., 2004; Agaimy et al., 2007]. 
The genetic progression of GIST beyond KIT mutations remains obscure, and the boundaries between 
focal hyperplasia of interstitial cells of Cajal and early neoplasia are unclear. Depending on their 
anatomic location, microscopic GIST may originate from heterogeneous subsets of interstitial cells 
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of Cajal with varying histopathological and molecular characteristics and different biological 
potential. 
Most of the information regarding GIST progression is based on low-resolution cytogenetic 
studies: many early GIST lesions show chromosomal aberrations such as loss of 14q and occasional 
losses of 1p, 22q, and 15q, intuitively considered indicators of a stepwise progression. Losses of 1p 
and 22q, may indicate transition to an unstable karyotype and higher potential for malignancy. 
Despite the identification of minimally overlapping regions in these chromosomes, discovering the 
specific gene targets involved in crucial steps of progression in GIST remains elusive. The application 
of next generation sequencing technologies has failed so far to unravel major oncogenes or tumor 
suppressor genes in GIST, with few exceptions, perhaps partly owed to the fact that this method is 
not optimal to detect small genomic deletions leading to loss-of-function of tumor suppressor genes. 
Further studies are ongoing to determine key events involved in tumor progression. Comparative 
genomic hybridization to determine chromosomal losses is generally not considered in establishing 
the diagnosis or performing risk stratification of GIST, given its limited accessibility. However, 
cytogenetic data may provide helpful additional information on the prognosis of GIST. Not 
surprisingly, GIST harboring a higher number of chromosomal aberrations (>5) are associated with 
a more aggressive clinical course [El-Rifai et al., 2000; Chen et al., 2004; Schaefer et al., 2014a]. 
Beyond the karyotypic information, a variety of cell cycle-related aberrations are thought to 
contribute to GIST progression, such as loss of p16 (CDKN2A), RB1 or, more rarely, deletion of 
TP53 [Schneider-Stock et al., 2003; Haller et al., 2008; Henze et al., 2012]. These are most likely 
late events in GIST progression, contributing a more aggressive clinical behavior and unfavorable 
prognosis. 
Recent studies from our group identified intragenic deletions of the dystrophin gene (DMD), 
located at Xp21, as a late event in GIST progression, and related to invasion and metastasis. 
(Publication I) DMD inactivation is observed in approximately 45% of myogenic cancers, including 
not only GIST but also leiomyosarcomas and rhabdomyosarcomas. Myogenic sarcomas with DMD 
inactivation show a higher rate of metastases as compared to early tumor stages or benign 
counterparts with preserved DMD function. Ongoing studies aim at validating dystrophin expression 
in GIST as a possible biomarker of malignant behavior and metastatic potential, as well as correlating 
expression levels with response to TKI therapy. Targeted gene therapies, already in use in patients 
with muscular dystrophies (type Duchenne or Becker), aim at restoring dystrophin function in muscle 
cell precursors. These therapeutic approaches in non-neoplastic diseases provide a compelling 
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opportunity to develop targeted therapies to restore or replace dystrophin function in myogenic 
cancers with DMD loss. 
Therapeutic options and mechanisms of resistance 
Surgery is the preferred treatment for localized GIST, with curative intent. Resection of a 
primary tumor with wide margins provides a 5-year disease specific free survival of ~50%. Following 
surgical resection, GIST tend to recur locally or spread to the peritoneum and liver [Fletcher et al., 
2002; Corless et al., 2011]; approximately half of the tumors relapse within 5 years, either as localized 
local recurrence (~7%) or as metastatic disease (~47%). In such setting, medical treatment with 
targeted therapy is preferred, since traditional chemotherapy (cytotoxic agents) is ineffective GIST 
(which explains the traditional dismal prognosis of GIST in the pre-targeted treatment era). Surgical 
resection of oligometastatic disease and tumor debulking have not yet proven to provide therapeutic 
benefit in clinical trials, but such approaches are being explored in research protocols. 
Imatinib mesylate has revolutionized the treatment of GIST since its introduction in 2001, and 
is now widely used as first-line therapy for advanced GIST [Joensuu et al., 2001; Demetri et al., 
2002]. GIST is the prototypical example of targeted inhibition of activating driver mutations to induce 
major clinical benefit for cancer patients. The preclinical demonstration of imatinib response in GIST 
cells, achieved in Dr. Fletcher’s laboratory, led to rapid clinical translation to treat patients with 
metastatic GIST, most of whom had major clinical responses [Demetri et al., 2002]; multicenter 
collaborative efforts provided the basis for regulatory approval of imatinib to treat advanced GIST 
[Heinrich et al., 2008b; Dematteo et al., 2009]. In these studies it was found that certain mutation 
subsets, e.g. KIT exon 11 mutations, respond particularly well to imatinib [Heinrich et al., 2003a]. 
After regulatory approval, imatinib treatment remarkably improved outcomes in GIST to the current 
median overall survival of 5 years for patients with metastatic GIST, compared to only 19 months in 
the pre-imatinib era [Dematteo et al., 2000; Blanke et al., 2008]. Approximately 80% patients with 
metastatic GIST initially respond to therapy (50% partial response, 30% stable disease) resulting in 
a 3-year survival rate of 69–74% [Verweij et al., 2004]. Primary drug resistance to imatinib mostly 
results from PDGFRA D842V point mutations or KIT/PDGFRA wild-type status [Heinrich et al., 
2008b]. The subset of tumors with KIT exon 9 mutations are less sensitive to standard dose of 
imatinib, but dose escalation to 800 mg/d provides efficient disease control.  Primary resistance due 
to hyperactivation of signaling effectors downstream KIT is possible, but much less common and 
probably reflects the need of activation of several signaling pathways by independent mechanisms 
(Publication II). In addition, even in patients with near-complete initial response to imatinib, there 
are invariably viable residual GIST cells, including drug-resistant subclones which subsequently 
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manifest as clinical progression 
[Heinrich et al., 2006]. In fact, 40-50% 
of GIST patients initially responding 
to imatinib develop secondary 
resistance within 2 years of therapy, 
which results from either secondary 
mutation in the ATP-binding pocket 
(exon 13-15), or the kinase activation 
loop (exons 17 or 18 of KIT and exon 
18 of PDGFRA) in the majority of 
cases (>50%), or, more rarely, 
KIT/PDGFRA genomic amplification 
or activation of alternative oncogenes 
[Fletcher et al., 2003; Debiec-Rychter et al., 2005; Liegl et al., 2008].  
Therefore, additional anti-KIT/PDGFRA drugs were evaluated. Sunitinib malate, which 
inhibits a broader spectrum of tyrosine kinases than imatinib, can induce control of the clinical disease 
and prolong survival when given second-line following failure of imatinib [Demetri et al., 2006; 
Heinrich et al., 2008a]. This work, led by the collaborative translational and clinical team at Dana-
Farber Cancer Institute/Harvard, served as the basis for worldwide regulatory approval of sunitinib 
as second-line agent for the treatment of imatinib-resistant advanced GIST. Unfortunately, response 
duration to sunitinib is relatively brief due to additional mutations of the kinase, typically occurring 
after 6-9 months of continuous sunitinib treatment [Heinrich et al., 2008a]. This fact is largely 
explained by the heterogeneity of the secondary mutations present in GIST cells that conferred 
imatinib resistance in the first place: work from our lab, in close collaboration with Drs. Michael 
Heinrich and Chris Corless at Oregon Health and Science University, has proven that the resistance 
mechanisms in GIST vary between different patients, between different metastatic lesions in a given 
patient, and even between different areas from the same lesion, but typically involve reactivation of 
the KIT/PDGFRA kinase through a range of secondary resistance mutations (Figure 3) [Heinrich et 
al., 2006; Desai et al., 2007; Liegl et al., 2008; Wang et al., 2010]. Some of the imatinib-resistant 
secondary KIT mutations, e.g. those affecting the ATP-binding pocket of the kinase, are sensitive to 
sunitinib; but others – e.g. those affecting the activation loop - are intrinsically cross-resistant 
[Heinrich et al., 2006]. Regorafenib, a fluoride derivative of sorafenib, has recently been approved 
for third-line treatment in GIST, as it is effective in cases with secondary sunitinib resistance and 
successfully targets secondary mutations in the kinase activation loop [George et al., 2012; Demetri 
Figure 3: Frequency of KIT mutations in imatinib-treated GIST. 
Resistance to TKI arises most often from secondary mutations in 
exon 13 (encoding the ATP-binding pocket) or exon 18 (encoding the 
kinase activation loop). Figure adapted from [Heinrich et al., 2006]. 
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et al., 2013]. Other multikinase inhibitors, like sorafenib (Publication III), nilotinib, dasatinib or 
crenolanib have shown modest activity against particular sets of mutations. The most recent 
compound within this group, ponatinib, has shown promising effects across a wide variety of 
mutations in preliminary studies [Heinrich et al., 2013]. In contrast to imatinib, multi-kinase 
inhibitors have a broader kinase inhibition profile but at the same time entail a higher toxicity and 
rate of adverse effects in patients.  
In addition to small molecule inhibitors, mutant KIT and PDGFRA can be potentially targeted 
using inhibitory chimeric antibodies. Recent studies provide evidence for the efficacy of a 
monoclonal anti-KIT antibody, designated SR1, to reduce cell growth in imatinib-sensitive and -
resistant GIST cell lines in vitro and in vivo [Edris et al., 2013]. SR1 treatment reduces cell-surface 
KIT expression, suggesting an antibody-induced KIT down-regulation to inhibit cell growth. 
Furthermore, SR1 induces phagocytosis of GIST cells by macrophages, indicating that SR1 may act 
as an opsonin and enhance immune cell-mediated tumor clearance [Edris et al., 2013].  
The structural heterogeneity of different KIT/PDGFRA oncoproteins complicates the design 
of drugs that could effectively bind to these mutant RTKs and inhibit the oncogenic signal in an 
efficient and specific manner. Indirect mechanisms to target KIT and PDGFRA oncoproteins may 
provide effective systems to overcome TKI resistance. KIT/PDGFRA signaling in GIST cells is 
exquisitely dependent on the chaperoning function of HSP90, which is required for folding, 
localization and stabilization of the mutant oncoproteins. Preclinical validations have shown 
compelling responses to HSP90 inhibition in GIST, in vitro and in vivo: after HSP90 inhibition by a 
variety of compounds, KIT oncoproteins are rapidly degraded, with antiproliferative and pro-
apoptotic consequences. Clinical translation of HSP90 targeting has been challenging, presumably 
because inhibition of HSP90 also targets HSP90-dependent, non-oncogenic, client proteins limiting 
the tolerance to sustained potent HSP90 inhibition. Initial clinical trials of ansamycin-analogue 
HSP90 inhibition in GIST have shown evidence of biological activity, although they achieved 
relatively low response rates and substantial toxicity [Wagner et al., 2013]. 
Besides direct or indirect targeting of KIT/PDGFRA, targeting the signaling pathways 
downstream of KIT/PDGFRA is a potentially effective and attractive strategy to by-pass the 
mutational heterogeneity of the oncogenic driver. Previous work from our lab has shown that most 
KIT/PDGFRA oncoproteins in GIST share common downstream signaling mechanisms, irrespective 
of their particular mutations and whether these are TKI-sensitive or TKI-resistant [Duensing et al., 
2004b]. Two main molecular pathways transduce the oncogenic signal downstream of KIT/PDGFRA 
and regulate proliferation and survival in GIST: the PI3K/AKT/mTOR pathway, and the 
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MEK/MAPK pathway, activated by GRB2/RAS/RAF mechanisms [Duensing et al., 2004b; Bauer et 
al., 2007; Zhu et al., 2007]. PI3K inhibitors LY294002 and GDC-0941 targeting PI3K mutations 
effectively decrease proliferation and induce cell death in various GIST cell lines in preclinical studies 
in vitro and in vivo [Floris et al., 2013]. Inhibition of PI3K by LY294002 substantially inhibits AKT, 
S6, and 4EBP-1 phosphorylation in GIST cell lines with PI3K and KIT expression levels remaining 
constant. Inhibition of mTOR has shown limited success, which has been ascribed to the activation 
of AKT that occurs following mTORC1 inhibition. Further drugs targeting the PI3K/AKT/mTOR 
pathway are currently being investigated in clinical trials in combination with imatinib, including the 
KIT/PI3K inhibitor BKM120, KIT/mTOR inhibitor everolimus, the mTOR inhibitor temsirolimus, 
and the KIT/AKT inhibitor perifosine [Schoffski et al., 2010]. Activation of RAS/RAF/MAPK 
signaling pathway may be targeted with MEK or BRAF inhibitors, such as trametinib or vemurafenib, 
currently used to treat BRAF-mutant melanoma. So far, only one GIST patient with a BRAF V600E 
mutation successfully treated with the ATP-competitive BRAF inhibitor dabrafenib has been reported 
[Falchook et al., 2013]. Given the activation of PI3K and MAPK pathways downstream KIT, it is not 
unexpected that dual inhibition of both pathways results in arrested proliferation and cell death in the 
preclinical setting. Toxicity of such combinations is still too high for them to be considered realistic 
options in the clinic, but novel compounds or improved administration regimens should enable dual 
downstream targeting. 
Understanding the molecular mechanisms of response and resistance to TKI therapy in GIST 
generates invaluable biologic insights, applicable to other tumor types driven by distinct oncogenic 
mutations. The mechanisms of resistance in malignancies as diverse as chronic myelogenous 
leukemia, EGFR- or ALK-driven non-small cell lung carcinoma, HER2-driven breast carcinoma or 
melanoma, are remarkably similar to those observed in GIST. Several features make GIST an ideal 
model for designing innovative therapeutic approaches to overcome drug resistance: first, the 
absolute addiction of GIST cells to sustained signaling from the KIT or PDGFRA oncogenic driver, 
with known signaling pathways that provide useful reference points. Second, the remarkably simple 
and stable genomic landscape characteristic of GIST. Third, the availability of unique cellular models 
that accurately represent the clinical reality. Finally, the availability of drugs and tool compounds 
with distinct specificity profiles, which provide unique tools to effectively modulate and study 
essential signaling pathways. In fact, GIST research has pioneered the development of targeted 
therapies, and successful translational efforts have led to the sequential approval of three lines of 
treatment, with highly effective targeted compounds that have had unmatched impact in patient 
survival. GIST provides an unprecedented opportunity to study in the laboratory the mechanisms of 
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drug response and resistance, combining information generated in the clinic and modeling innovative 
approaches that can be tested with greatest likelihood of clinical translation. 
Functional genetic screens 
An enhanced understanding of the signaling networks and the molecular mechanisms of 
growth and survival in tumor cells, and in GIST cells in particular, will allow us to rationally develop 
additional therapeutic strategies, with maximal likelihood of prolonged clinical success. The 
addiction of GIST cells to their KIT/PDGFRA oncogenic drivers imposes secondary dependencies 
on genes that are not oncogenes in and of themselves, but which can be inhibited therapeutically in 
GIST as KIT/PDGFRA oncogene-specific “synthetic lethal” strategies [Scholl et al., 2009]. As a 
consequence, targeting KIT/PDGFRA or its downstream effectors will likely remain the main focus 
of GIST therapy, but additional targets will be exposed if the key nodes and vulnerabilities resulting 
from the oncogenic status can be discovered. Several high-throughput technologies allow the 
interrogation of multiple variables in a multiplexed manner in cancer cells; the most common and 
available of such techniques is the systematic characterization of cancer cells genome –as illustrated 
by the profusion of genomic studies, spearheaded by consortium efforts like The Cancer Genome 
Atlas, TCGA. Such genomic annotations reveal the genetic make-up of cancer cells, including 
mutational load and copy number information; cataloging cancer mutations offers critical insights 
into the biology of malignancy, based in structural information (i.e. integrity of genes or their 
abnormalities). However, to understand the function of the cancer genome and the genetic 
dependencies of cancer cells, a complementary set of functional genomic approaches is required. 
Descriptive information of additional cellular “-omes” provide complementary angles (such as 
transcriptome, proteome, metabolome or secretome), while functional techniques allow for 
experimental manipulations at a genomic scale (Figure 4). 
Functional genomic techniques aim to characterize the functional relevance of individual 
genes in relationship to a given phenotype. Instead of analyzing if a gene sequence or dosage is 
normal or abnormal in a cancer cell, functional approaches provide information regarding the relative 
importance of each gene for the cancer cells to accomplish certain cellular functions, such as survive, 
proliferate, invade, or metabolize a given compound. This approach is interventional, rather than 
descriptive, since the cells are subject to genetic manipulations and then closely followed to document 
the resulting phenotype. Functional genetic manipulations have been utilized for decades in molecular 
biology, but recent technological advances, combined with a better understanding of some molecular 
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processes (such as gene silencing through RNAi) have enabled highly-parallel multiplexing of genetic 
perturbations. Two complementary approaches can be used for functional genetic experiments: loss-
of-function assays, performing RNAi-mediated gene knockdown with shRNAs (short-hairpin RNAs) 
[Luo et al., 2008] or Cas9-mediated knockout with sgRNAs (short guide RNAs) [Shalem et al., 
2014]; and gain-of-function experiments, inducing high-throughput ORF-mediated gene expression 
utilizing lentiviral expression vectors [Johannessen et al., 2010; Yang et al., 2011]. Collections of 
reagents have been developed in the form of libraries that enable genetic perturbations at a genome-
wide scale. One such collection is The RNAi Consortium (TRC) developed at the Broad Institute, a 
biomedical research institute located in Boston (Massachusetts, USA) and founded as a collaboration 
between Harvard University and the Massachusetts Institute of Technology. The TRC library hosted 
at the Genetic Perturbations Platform of the Broad Institute consists of shRNA, sgRNA and ORF 
(open reading frame) libraries that cover the entire human and mouse genomes. 
To identify cellular dependencies and the underlying responsible genes, either involved in 
essential GIST growth/survival pathways or in drug resistance, we performed genome-wide 
functional evaluations using the TRC libraries. The experiments described in this work correspond to 
pooled loss-of-function shRNA approaches, given that the ORF and sgRNA libraries were not fully 
developed at the beginning of this project (although more recent experiments within our group utilize 
sgRNA and ORF libraries). 
Figure 4: Systematic genomic approaches to study cancer biology. The impact of functional genomic screens is 
maximized by the integration with orthogonal technologies like genome characterization by massively parallel 
sequiencing and copny number analysis. Figure adapted from [Boehm and Hahn, 2011]. 
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The technology of pooled shRNA libraries was developed to perform unbiased comprehensive 
loss-of-function genetic screens and allows for the systematic correlation of gene knockdowns with 
a given cellular phenotype in a high-throughput manner [Cheung et al., 2011]. Each shRNA, a 
synthetic double-stranded RNA of approximately 21nt, triggers degradation of a cellular messenger 
RNA, which is cleaved by a protein of the Argonaute family within the RNA-induced silencing 
complex. The extent to which the target mRNA is degraded is variable, and is referred to as the 
‘knockdown efficiency’ for each particular shRNA. The specificity of shRNAs for mRNA targets is 
also variable, and off-target effects are common events in RNAi experiments (see Discussion). Given 
that any single shRNA may function in both on- and off-target pathways, proper interpretation of 
shRNA experiments requires that multiple independent shRNA targeting the same gene result in the 
same phenotype. shRNA libraries are hence redundant and incorporate multiple shRNAs per gene. 
In its current iteration, the TRC shRNA library consists of 98,000 shRNA constructs corresponding 
to 18,000 human genes, with ~6 non-overlapping hairpins per gene, which can be delivered to the 
cells of interest in a single pooled lentiviral infection. The shRNAs are introduced into retroviral 
vectors through conventional cloning methods; in its lentiviral form, the DNA sequence of the 
perturbation is delivered into the genome of the host cell, resulting in a permanent, heritable genomic 
modification that leads to constitutive expression of shRNAs in the host cell. 
Pooled screening assays may follow two general experimental designs: positive or negative 
selection screens, depending on the phenotype under consideration. The simplest example of a 
negative selection phenotype is cell death: perturbations that cause cells to die are depleted from the 
population over time. Such an approach has been used to identify genes that are broadly essential to 
cell viability, as well as to identify essential genes to specific cell types [Cheung et al., 2011]. A 
large-scale approach using this methodology is underway in an effort called Project Achilles, which 
aims to systematically characterize cancer cell vulnerabilities for a wide variety of tumor types. The 
Project Achilles dataset is publicly available online (http://www.broadinstitute.org/achilles) and to 
date includes data on 216 cell lines as described in a recent publication by Glenn Cowley and 
collaborators [Cowley et al., 2014]. A limiting characteristic of negative selection assays is that a 
perturbation can only be depleted to zero, from the starting level at which it was present in the original 
pool. This results in limited signal-to-noise ratio for negative selection screens with large libraries, 
compared to smaller sub-libraries. Positive selection screens focus instead on cell survival, relying 
on overrepresentation of a subset of cells in response to a given perturbagen in the population; 
therefore, they have a much larger dynamic range. Examples of positive selection screens include 
viability assays to rescue cells from a toxic intervention, such as a pharmacologic inhibitor, or 
detection of specific markers induced by transcriptional activators [Wilson et al., 2015]. 
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The design of the 
experiments described in this 
work, in brief, is as follows: 200-
300 million GIST cells are 
infected in a single pooled 
infection with the complete 
shRNA library, for a 
representation of 200-300 cells 
per shRNA. Infected cells are 
selected with puromycin, and six 
experimental replicates are set up 
in parallel. The cells are then 
expanded under different 
selective conditions (untreated or 
under pharmacologic inhibition 
of KIT/PDGFRA) and after ~16 doublings the representation of the initial shRNA library is assessed 
by genomic DNA extraction, sequencing, and quantification of the relative proportion of hairpins in 
the surviving cells (Figure 5). Several computational algorithms are applied to collapse information 
from multiple hairpins to the corresponding genes, the resulting output being a bidirectional rank of 
genes according to depletion or enrichment in the final population. This conversion of hairpin-level 
data to gene-based information is complex and relies on several computational algorithms that have 
been developed as our understanding of the RNA interference process improved. shRNA reagents 
induce different degrees of on-target and off-target effects, and gene suppression resulting from both 
sources may contribute to the phenotype of interest. The use of different computational approaches 
allows for a good discrimination of on-target effects, or at least provides a level of confidence in the 
results that can be used before embarking on downstream validation experiments (see Discussion 
section). Once several analyses are performed, the definition of a “hit” may be controversial, but is 
usually established in statistical terms based on false discovery rate and p-value thresholds. We 
focused on the extremes of the distribution (top 1%, top 5%, and top 10% of ranked genes), but the 
signal-to-noise ratio in some of the analyses suggests that the gene ranks provide valid information 
also for less extreme values. In any case, follow-up confirmatory experiments are performed with 
independent shRNAs and other reagents to validate the results. 
A complementary aspect to shRNA pooled library screens is the high-throughput gain-of-
function screening technology, currently at an earlier stage of development. A lentiviral expression 
Figure 5: Experimental design for shRNA pooled screens to identify 
essential genes, specific cell dependencies, and synthetic lethal interactions 
in GIST. 
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library created at the Broad Institute comprises 18,000 distinct ORFs mapping to ~16,000 genes 
[Yang et al., 2011]. Positive selection ORF screens are particularly suited for the study of resistance 
to pharmacologic inhibitors. Specific challenges of this experimental design include the difficulty to 
generate physiologic levels of expression, and the limited representation of transcript variants. 
Nevertheless, the juxtaposition of gain-of-function data to our GIST shRNA screening datasets will 
maximize opportunities to identify crucial biologic pathways, i.e. targets and pathways that are 
convincingly identified as crucial regulators of GIST viability in both the loss-of-function and gain-
of-function evaluations.  
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Hypotheses and Specific Aims 
Previous studies have highlighted that Gastrointestinal Stromal Tumors (GIST) provide 
compelling opportunities to target oncogenic driver mutations. Most GIST depend upon continuous 
signaling through mutant constitutively-activated forms of KIT or PDGFRA, and biologically 
credible in vitro GIST models have enabled efficient, highly-informative validations of therapeutic 
strategies relevant to the mutant KIT/PDGFRA kinase pathways. Targeted KIT/PDGFRA inhibition 
with small molecules like imatinib has profound effects on GIST viability and growth and, 
accordingly, most GIST patients exhibit remarkable clinical responses upon treatment with such 
inhibitors. However, ~90% of clinically advanced GIST are composed of heterogeneous populations 
of cells that harbor a range of imatinib-resistant secondary KIT/PDGFRA mutations, which cannot 
be durably suppressed by any given KIT/PDGFRA inhibitor and eventually lead to clinical 
progression. Importantly, the genetically diverse KIT/PDGFRA oncoproteins, irrespective of their 
variable sensitivity to tyrosine kinase inhibitors, share common downstream signaling mechanisms 
in GIST cells, including activation of the MEK/MAPK and PI3K/AKT/mTOR pathways. We 
hypothesize that a nuanced understanding of these constitutively activated signal transduction 
pathways will uncover vulnerabilities that can serve as biologically rational targets for combination 
therapies to maximize the clinical benefit of KIT/PDGFRA inhibition. With this objective in mind, 
we seek to expand the current knowledge of GIST biology and to design effective therapeutic 
strategies that will overcome TKI resistance in GIST patients.  
The overarching goal of this project was to improve the long term survival of GIST patients 
by designing novel efficient combination therapies. To this end, we performed functional studies of 
GIST cells for target discovery and preclinical validations of optimal GIST therapeutic strategies 
according to a research plan with the following specific aims: 
Aim 1: To establish a functional genomics platform to discover novel gene dependencies 
and biologic vulnerabilities in sarcoma cells. With the goal of systematically interrogating 
functional dependencies on a genome-wide scale in patient-derived cellular models of sarcoma, we 
established a working collaboration with the Genetic Perturbation Platform at the Broad Institute of 
MIT and Harvard. We customized the experimental conditions to optimally evaluate large scale 
sarcoma cultures, both for loss-of-function pooled screening as well as, on a second phase, for gain-
of-function arrayed experiments. The reagents and infections were performed at the Broad Institute, 
while large-scale cell culture expansion took place at Brigham and Women’s Hospital. 
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Aim 2: To characterize essential genes and pathways involved in GIST proliferation and 
survival. To identify essential genes in GIST, we performed loss-of-function genome-scale shRNA 
screens in three GIST cell lines, using pooled lentiviral libraries (54K shRNAs, targeting 11K genes) 
within the RNAi Consortium at the Broad Institute of MIT and Harvard. We have validated the 
highest scoring leads, with follow-up individual functional assays and pharmacological inhibitors. In 
ongoing experiments, we are undertaking a complementary but orthogonal approach, in which gain-
of-function screens will be performed in the same GIST lines using novel ~16K cDNA open reading 
frame (ORF) expression libraries. 
Aim 3: To identify mechanisms of drug response and resistance, and discover synthetic 
lethal interactions with KIT/PDGFRA inhibition in GIST cells. The Aim 2 genome-scale screens 
will be leveraged by modifier screens performed with IC50 doses of KIT/PDGFRAi (imatinib and 
sunitinib). In these studies we will identify targets whose suppression synergizes with KIT/PDGFRA 
inhibition, as well as genes whose expression rescues the cells by conferring resistance to treatment. 
The goal is to identify effective combination therapies for GIST. 
Aim 4: To validate novel rationally-designed targeted therapeutic strategies for GIST. 
The functional datasets generated by the Aim 2 and Aim 3 high-throughput screens will be leveraged 
by our parallel sequencing studies in GIST (exome and whole genome sequencing, transcriptome 
sequencing). To maximize the insights from these datasets, we will triangulate the genomic, 
expression profiling and functional data to prioritize potential targets for preclinical validations. The 
requisite bioinformatic analysis will be accomplished with assistance from our computational biology 
team at the Broad Institute, and the preclinical validations will be performed using knockdown 
methods and selective pharmacologic inhibitors of the priority targets. 
The results presented in this dissertation correspond to the completion of Aims 1 and 2 of this 
large, multi-institutional project, which has been developed over the last 5 years. Aims 3 and 4 are 
being pursued in ongoing experiments, and will likely take several years for completion. Within this 
highly translational research work, we are utilizing innovative technologies to systematically 
characterize cellular models of GIST that accurately represent the clinical disease. Collectively, these 
studies will foster the development of urgently needed effective combination therapies by identifying 
vulnerabilities and synthetic lethal interactions in GIST cells. In addition, the mechanistic insights 
resulting from these studies will be relevant to other kinase-dependent sarcomas. 
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Material and Methods 
Cell lines 
GIST882 is an imatinib-sensitive human cell line established from an untreated GIST with a 
primary homozygous missense mutation in KIT exon 13, encoding a K642E mutant KIT oncoprotein 
[Bauer et al., 2006]. GIST-T1 is an imatinib-sensitive GIST cell line established from an untreated 
metastatic GIST containing a homozygous 57 bp deletion in KIT exon 11 [Taguchi et al., 2002]. 
GIST430 and GIST48 are KIT exon 11 mutant GISTs established from patients progressing clinically 
on imatinib; these, respectively, have V654A ATP-binding pocket and D820A activation loop 
secondary imatinib-resistance mutations [Bauer et al., 2006]. GIST48B is a subline of GIST48 which, 
despite retaining the activating KIT mutation in all cells, expresses essentially undetectable levels of 
KIT transcript and protein. GIST882 and GIST-T1 cells were maintained in RPMI 1640 with 15% 
fetal bovine serum (FBS) supplemented with penicillin/streptomycin and 1% (v/v) L-glutamine. 
GIST48 and GIST430 were maintained in Ham’s F10 culture medium containing 15% FBS, 
penicillin/streptomycin, L-glutamine, Mitotracker+, and bovine pituitary extract. All GIST lines used 
in this study were cultured from highly-credentialed master stocks (KIT mutation sequencing 
authentications and 250K NspI SNP whole-genome profiles) for no more than three months before 
being used in the assays. HEK293T cells obtained from ATCC were used to produce lentiviral 
constructs. 
Primary shRNA pooled screen 
Development and applications of the 54K lentiviral shRNA pooled library from The RNAi 
Consortium (TRC) have been described recently in the literature [Cheung et al., 2011]. For this 
particular screen, GIST-T1 and GIST882 cells were infected with a pool of 54,020 pLKO.1-shRNA-
encoding lentiviruses targeting 11, 194 genes at a multiplicity of infection of ∼0.3 and subjected to 
puromycin selection (2 μg/mL) for 5 days. Eight (GIST-T1) and six (GIST882) replicates of ~20 
million cells were established post-selection and plated in T175 flasks, fed on a 3-times-per-week 
schedule and passed at confluence, approximately weekly. For every passage, a minimum of 12x10E6 
cells was passed into new flasks for continued culture and expansion over 6-7 weeks, while the 
remaining cells were harvested by centrifugation, resuspended in 0.5 ml PBS, and stored at -20ºC for 
subsequent genomic DNA extraction and analysis. Final harvests of the infected cells were used for 
genomic analysis according to the previously validated methods: genomic DNA was isolated from 
cell pellets by digestion with proteinase K followed by isopropanol precipitation. To amplify the 
shRNAs encoded in the genomic DNA, PCR was performed for 33 cycles at an annealing temperature 
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of 66°C using 2–6μg of genomic DNA, a barcoded primer pair, and DNA polymerase. So that PCR 
products obtained from different samples could be sequenced together, forward primers containing 
unique 2-nucleotide barcodes were used [Barcoded forward primer: AATGATACGGCACCACCG 
AGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAANNGACGAAAC (N indicates 
location of sample-specific barcode sequence). Common reverse primer: CAAGCAGAAGA 
CGGCATACGAGCTCTTCCGATCTTGTGGATGAATACTGCCATTTGTCTCGAGGTC]. After 
purifycation, the PCR products were quantified by ethidium bromide staining after gel 
electrophoresis, pooled at equal proportions, and analyzed by high-throughput sequencing (Illumina) 
using this primer: AGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAA. Sequencing reads 
were deconvoluted using GNU Octave software by segregating the sequencing data by barcode and 
matching the shRNA stem sequences to those expected to be present in the shRNA pool, allowing 
for mismatches of up to 3 nucleotides. The 54,020 shRNAs were ranked by their relative depletion 
from the cell pool, and the corresponding 11, 194 genes, were then scored according to the rank of 
the second-most depleted shRNA (out of typically 5 shRNAs targeting each gene). The in-house-
developed GENE-E program was used to rank the genes according to the second best-scoring shRNA 
within each hairpin set (http://www.broadinstitute.org/cancer/software /GENE-E/download.html). 
Preparation of lentiviral shRNA constructs for validations 
Lentiviral constructs encoding shRNA specific sequences targeting CDC37 and KIT gene 
transcripts on the pLKO.1puro backbone were selected from the TRC library (TRCN0000116632-
TRCN0000116636 and TRCN0000000388- TRCN0000000392; the TRC website is 
http://www.broadinstitute.org/rnai/trc/lib). Lentivirus preparations were produced by lipofectamine-
mediated cotransfection into HEK293T cells of pLKO.1puro containing empty vector or 
CDC37/KIT-specific shRNA, and helper virus packaging plasmids Δ8.9 and VSV-G (at a 10:10:1 
ratio). Culture supernatants containing lentivirus were collected 24, 36, 48 and 60 h post-transfection. 
Viral preparations were pooled and stored at -80°C. Well-validated shRNA providing >90% 
knockdown were used for CDC37 knockdown in follow-up experiments (TRCN0000116632: clone 
1; and TRCN0000116633: clone 2). 
Validation cell culture and lentiviral infections 
GIST cells were seeded in 6-well plates and lentiviral infections were performed overnight in 
the presence of 8 μg/mL polybrene. Following infection, shRNA-expressing cells were selected with 
2 μg/mL puromycin. GIST882 and GIST-T1 cells were maintained in RPMI 1640 with 15% fetal 
bovine serum (FBS) supplemented with penicillin/streptomycin and 1% (v/v) L-glutamine. GIST48 
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and GIST430 were maintained in Ham’s F10 culture medium containing 15% FBS, 
penicillin/streptomycin, L-glutamine, Mitotracker+, and bovine pituitary extract. Cell culture images 
by bright field microscopy were obtained using SPOT software (SPOT Imaging Solutions, Sterling 
Heights, MI, USA) and an Eclipse TE2000-5 inverted microscope (Nikon, Japan). Cells were lysed 
for western blot analysis at 4, 10 and 20 days post-infection. 
Antibodies and other reagents 
Antibodies for immunoprecipitation were to KIT (sc-13508; Santa Cruz Biotechnology) and 
CDC37 (ab2800; Abcam). Antibodies for immunoblotting were KIT (A4502; Dako), CDC37 
(ab2800; Abcam), phospho-KIT Y721 (3391s; Cell Signaling Technologies), phospho-AKT S473, 
total AKT and phospho-MAPK T202/T204 (9271L; 9272 and 9101L, respectively; Cell Signaling 
Technologies), MAPK (61-7400; Invitrogen), and actin (A4700; Sigma-Aldrich). Lipofectamine™ 
and Plus Reagent™ were from Invitrogen. Puromycin and polybrene were from Sigma-Aldrich. 
Western blotting and immunoprecipitation 
Whole cell lysates were prepared from cell line monolayers in lysis buffer (1% NP-40, 50 mM 
Tris-HCl pH 8.0, 100 mM sodium fluoride, 30 mM sodium pyrophosphate, 2 mM sodium molybdate, 
5 mM EDTA, 2 mM sodium orthovanadate) containing protease inhibitors (10 μg/mL aprotinin, 10 
μg/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride). Protein concentrations were determined 
with the Bio-Rad Protein Assay (Bio-Rad Laboratories). Electrophoresis and immunoblotting were 
carried out as described previously [Rubin et al., 2001]. Detection was by chemiluminescence 
(Immobilon Western, Millipore Corporation), with image capture by a FUJI LAS1000-plus 
chemiluminescence system. KIT and CDC37 immunoprecipitations were performed using 
Sepharose-protein G beads (Invitrogen). 
Cell cycle analysis 
Analyses were performed 10 days after lentiviral infections with puromycin selection. 
GIST882, GIST-T1 and GIST430 cells in 6-well plates were trypsinized, pelleted, and then washed 
once with Hanks Balanced Salt Solution at room temperature. For nuclear DNA content staining, 
cells were fixed with 70% ethanol for 24 h. For nuclear staining, propidium iodide (PI) solution 
(Roche) was added to the cells and incubated for 15 minutes at 37°C. The cell suspension was 
analyzed in a flow cytometer (NPE Quanta, NPE Systems) and data analysis was performed using 
ModFit LT software 3.1 (Verity Software House, Topsham, ME). 
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Cell viability assays 
Cell viability studies were carried out using the CellTiter-Glo luminescent assay (Promega, 
Madison, WI), in which luciferase-catalyzed luciferin/ATP reaction provides an indicator of cell 
number and metabolic activity. GIST cell lines were plated at 5,000 or 10,000 cells per well in 96-
well flat-bottomed plates (Falcon, Lincoln, NJ) and cultured for 12 days post-infection in serum-
containing media. The CellTiter-Glo assay luminescence was measured with a Veritas Microplate 
Luminometer (Turner Biosystems, Sunnyvale, CA) at days 0, 4, 8 and 12. Readings were normalized 
to the day 0 and pLKO control reads. All experimental points were measured in triplicate wells and 
replicated in at least two independent plates. 
Xenograft studies 
All mice used were maintained, injected and sacrificed in accordance with an approved 
IACUC protocol at Dana Farber Cancer Institute. Athymic nude mice were injected subcutaneously 
with GIST-T1 cells expressing CDC37-targeting shRNA in one flank (shRNA1: TRCN0000116632; 
shRNA 2: TRCN0000116633; n=3 each) and empty pLKO.1 lentiviral vector in the other flank (n=3). 
In all, 2 × 106 infected cells on puromycin selection were resuspended in Matrigel (BD Biosciences) 
and implanted subcutaneously at each injection site. Tumor volume was evaluated weekly. Mice were 
killed by CO2 inhalation and necropsied 6 weeks after injection. Tumors were resected, measured and 
photographed. Whole tumor lysates were prepared for Western blot analysis (as described above), 
and tissue was fixed in formalin for routine histologic processing and examination. 
  
 31/92 
Results 
shRNA pooled library screen performance in GIST-T1 and GIST882 cells 
The reproducibility of short hairpin RNA (shRNA) enrichment and depletion profiles was 
evaluated across the experimental replicates, as a quality control. The GIST882 and GIST-T1 screen 
replicates clustered closely within each cell line by both unsupervised and consensus clustering of 
shRNA depletion and enrichment profiles, attesting to the robustness of the screens. In addition, the 
GIST882 and GIST-T1 replicates clustered next to each other when compared with a reference data 
set of 12 publicly available cancer cell line data sets [Luo et al., 2008], as well as after linkage analysis 
in the context of additional unpublished sarcoma cell lines (Figure 6). A comprehensive list of the 
11,194 ranked genes, along with annotation for the shRNA clones, is provided in Table 1. 
Figure 6: Similarity matrix and unsupervised hierarchical clustering of the shRNA profiles of 6 sarcoma cell lines, 
cultured after pooled infection with the TRC shRNA library (Pearson correlation; average linkage analysis), showing 
clustering of the replicates corresponding to each cell line. 
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CDC37 is essential for GIST cell survival 
In the pooled proliferation screens, cells carrying shRNAs that targeted proliferation-essential 
genes were depleted from the cell population over time. Scored according to the second best-scoring 
shRNA within each hairpin set, 25 out of 56 genes ranked in the top 0.5% of the distribution for both 
GIST882 and GIST-T1 (Table 1, left column). Of these 25 genes, 19 were also within the top 0.5% 
in at least 8 of 12 comparison non-GIST cancer lines [Luo et al., 2008], and were thus identified as 
‘commonly essential’ genes not specific to GIST (Figure 7). These genes belonged to functional 
categories known to be essential in cancer cell lines: regulation of mRNA splicing and processing, 
protein translation, and ribosome and proteasome structure and function. The other six genes were 
selectively essential for the two GIST cell lines vs the other lines (bold italic font, Table 1 left 
column): five of these encode mRNA processing proteins, whereas the remaining gene, CDC37, 
encodes an HSP90 cofactor. CDC37 is known to coordinate HSP90 chaperoning activity for a subset 
GIST882 and 
GIST-T1 
GIST882 
only 
GIST-T1 
only 
CDC37 
POLE 
RPS18 
PSMA3 
SFRS3 
EIF3S10 
RPS13 
RPS29 
RPL23A 
PSMB2 
RPL5 
RPS9 
RPS17 
RPL31 
ARCN1 
PHB2 
RPS7 
RPS27A 
RPS8 
RPS15A 
PSMD1 
U2AF2 
CHD4 
AQR 
NHP2L1 
UBC 
DYNC1H1 
VCP 
HNRPK 
PABPN1 
SNRPD1 
PSMC1 
FRAP1 
AFG3L2 
LOC375133 
PSMA6 
EIF3S5 
TSG101 
PTPRCAP 
TUBB 
RPS19 
KARS 
SNRPD2 
PSMA1 
RPS14 
HNRPU 
RPS6 
RPS3 
ASCC3L1 
RPL34 
NDUFA4L2 
RPSA 
USP39 
PHB 
EIF1AX 
TPR 
PSMC4 
EFTUD2 
PSMA2 
PRPF3 
NCBP2 
ABCB7 
EIF3S3 
ATPBD1C 
RPAP1 
RBM8A 
DDX48 
RNPS1 
COPS2 
RPS10 
MLXIP 
ATP1A1 
POLR2F 
RUVBL2 
NUP205 
MKI67IP 
RAN 
RPS3A 
RPS4X 
RPS11 
RPL7 
RPL6 
EIF5B 
EIF2S2 
SNRPE 
HSPE1 
U2AF1 
Table 1: Top 0.5% essential genes according to the second best 
scoring hairpin in GIST882 and GIST-T1 (n=56 for each). Genes 
in bold font (upper fields) scored top 0.5% in the gene distribution 
in GIST lines but not in 12 non-GIST reference cancer cell lines of 
various lineages (described by Luo et al.15). Genes in regular font 
(lower fields) scored top 0.5% in both GIST and the 12 non-GIST 
reference set. 
Figure 7: Most of the top 0.5% essential genes for GIST882 and 
GIST-T1 were commonly essential genes, based on their ranks in 
at least 8 of 12 non-GIST cancer cell lines of various lineages. 
However, six genes, including CDC37, were selectively essential 
in GIST882 and GIST-T1 compared with the non-GIST lines. 
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of HSP90 client proteins, including several kinases [Vaughan et al., 2008; Smith and Workman, 
2009], by mechanisms involving CDC37 homodimerization, CDC37-HSP90 heterodimerization and 
the formation of CDC37-kinase-HSP90 complexes [Xu et al., 2012]. These observations suggest that 
CDC37 targeting might be a selective approach to derailing HSP90-mediated KIT oncoprotein 
chaperoning in GIST. The KIT oncogenic driver and the GIST-lineage-related transcription factor 
ETV1 also scored as essential genes in these primary screens and serve as positive controls (Figure 
8).  In GIST-T1 cells, only one out of the five shRNAs targeting KIT was highly depleted, so KIT did 
not rank highly in the essential genes list; however, subsequent experiments showed that only the 
strongly depleted shRNA was highly effective at suppressing KIT in these cells (~70% knockdown) 
whereas the other four shRNAs produced <30% 
KIT knockdown (Figures 8 and 9).  
 
Figure 8: Gene ranks (red) and shRNA ranks (black) corresponding to CDC37, KIT and ETV1 in GIST882 cells (left) 
and to KIT in GIST-T1 cells (right). Essential genes (oncogenes) rank on the top of the distribution 
Figure 9: Protein immunoblotting demonstrating low 
knockdown efficiency of the 5 KIT-targeting shRNAs 
present in the library, in GIST-T1 cells.  
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CDC37 interacts with KIT in GIST, maintaining KIT expression and cell survival 
CDC37 expression was demonstrated by immunoblotting in the GIST cell lines (Figure 10). 
Interaction between CDC37 and KIT in these GISTs was demonstrated by co-immunoprecipitations 
using KIT and CDC37 antibodies in KIT-positive GIST882 and GIST-T1 cells, with KIT-negative 
GIST48B cells serving as a negative control (Figure 10). CDC37 shRNA-mediated knockdowns 
resulted in >90% reduction of KIT expression and activation in the KIT-dependent GIST882, 
GIST430 and GIST-T1 lines (Figure 11). KIT inhibition was associated with inactivation of 
downstream growth and survival signaling intermediates, including AKT. By contrast, AKT was not 
inhibited by CDC37 knockdown in the KIT-negative cell line GIST48B, suggesting that the observed 
inhibition of downstream signaling pathways in GIST882, GIST430 and GIST-T1 was KIT 
dependent (Figure 11).  
 
Figure 10:  CDC37 expression and CDC37-KIT co-immunoprecipitations 
in GIST cell lines, demonstrating CDC37:KIT interaction. 
Figure 11:  Persistent inhibition of KIT oncoprotein expression and phosphorylation, and decreased downstream 
signaling pathway activation in KITdependent GIST cells on shRNA-mediated CDC37 knockdown. 
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CDC37 knockdown, unlike direct HSP90 inhibition [Chandarlapaty et al., 2008], resulted in 
persistent inhibition of KIT expression for >20 days, indicating that GIST cells have few 
compensatory pathways for CDC37 function. The above-mentioned biochemical responses to 
CDC37 knockdown were accompanied by decreased GIST proliferation and survival as assessed by 
bright field microscopy and CellTiter-Glo assays (Figures 12A and 12B). Notably, these responses 
were also seen in GIST lines resistant to imatinib (GIST430) or to the ansamycin HSP90 inhibitor 
17-AAG (GIST-T1/AAG and GIST882/AAG). CDC37 knockdown induced an increased sub-G0 cell 
cycle peak, consistent with a pro-apoptotic effect (Figure 12C). 
shRNA-mediated CDC37 knockdown in GIST-T1 cells resulted in significantly decreased 
growth in vivo, with decreased tumor volume over a 6 week period, overall decreased tumor 
cellularity and decreased mitotic activity in subcutaneous mouse xenografts (Figure 13).  
 
 
 
Figure 12: shRNA-mediated CDC37 knockdown inhibits viability of GISTs, including those resistant to imatinib 
(GIST430) and to the ansamycin-type HSP90-inhibitor 17-AAG (GIST882/ AAG and GIST-T1/AAG) as demons-trated 
by cell morphology (A), ATP-based cell viability (B) and by the increase in the number of cells in sub-G0 phase of the 
cell cycle, 10 days after lentiviral infection and puromycin selection (C). 
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 Celastrol does not enable selective CDC37:HSP90 pharmacologic inhibition 
Preclinical pharmacologic validations were attempted using celastrol, a natural product 
reported to inhibit the HSP90:CDC37 interface [Zhang et al., 2009]. Celastrol nonselectively 
inhibited viability of both KIT-dependent and KIT-independent (GIST48B) GIST cell lines (Figure 
14A), and celastrol treatment did not result in dramatic dose-dependent inhibition of KIT expression 
or KIT activation, despite reduced AKT and mitogen-activated protein kinase phosphorylation 
(Figure 14B). These findings underscore the protean effects of celastrol, which are reported to 
Figure 14: (A) Dose-dependent reduction of GIST cell viability by the HSP90:CDC37 interface inhibitor celastrol, 
despite persistent expression and activation of KIT (B). 
Figure 13:  shRNA-mediated CDC37 knockdown inhibits growth of GIST xenografts in mice. (a, b) Significantly 
decreased tumor growth on CDC37 knockdown. (c) Western blot confirming inhibition of CDC37 expression in GIST-
T1 cells infected with CDC37 shRNA1 and shRNA2, compared with pLKO.1 lentiviral vector. (d) Histologic evaluation 
of demonstrates sparsely cellular areas with no mitotic activity in CDC37-knockdown GIST xenografts, in comparison 
with highly cellular and mitotically active xenografts of pLKO.1-infected cells. 
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include proteasome inhibition [Zhang et al., 2009], and which will likely preclude achieving 
CDC37:HSP90-inhibitory drug concentrations in the clinical setting. We therefore expect that 
effective clinical translation of CDC37 inhibition will require development of potent and more 
selective CDC37 inhibitors. Opportunities for selective CDC37 targeting might result from 
pharmacologic dysregulation of phosphorylation at CDC37 Ser13. This phosphorylation event—
mediated by casein kinase 2—is requisite for CDC37 recruitment of kinase clients to the HSP90 
complex, whereas CDC37 Ser13 dephosphorylation—mediated by protein phosphatase 5—is then 
necessary for priming CDC37 for tyrosine phosphorylation by YES1, ultimately enabling CDC37 
and client release from the complex [Xu et al., 2012] . Therefore, strategies targeting casein kinase 
2, protein phosphatase 5 or YES1 might inhibit KIT-directed HSP90 functions in GIST. 
 
In summary, we performed unbiased genome-wide loss-of-function genomic screens, which 
identified CDC37 as a compelling therapeutic target in GIST. CDC37 interacts with KIT oncoproteins 
in GIST and is an essential enabler of KIT oncogenic function. Preclinical validations highlight the 
selectivity and efficacy of targeting KIT through CDC37 in GIST, with advantages compared with 
direct HSP90 targeting including persistent downregulation of KIT expression and selectivity for only 
a subset of HSP90 client proteins. These observations suggest that selective targeting of CDC37 
might be effective and less toxic than chronic HSP90 inhibition in GIST patients. 
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Discussion 
Remarkable progress has been made in the past two decades towards understanding the 
biology of GIST, resulting in improved clinical outcomes through the rational development of 
targeted therapies. The discovery of KIT/PDGFRA activating mutations in GIST, followed by the 
extremely successful repurposing of imatinib for GIST treatment -from its original conception as a 
BCR-ABL inhibitor, for the treatment of chronic myelogenous leukemia-, has transformed the field 
of solid tumor therapeutics. More recently, the understanding of resistance mechanisms led to the 
approval of first sunitinib, and then regorafenib, as sequential second and third line treatments for 
progressing disease. At present, GIST represents the most successful example of translational 
research applied to the development of targeted therapies for solid tumors, having three targeted 
agents providing clinical benefit in sequential administration. Up to 10% of patients with metastatic 
disease achieve long term disease control (>10 years) on single-agent imatinib. Sunitinib and 
regorafenib provide further disease control of relatively short duration, and no alternative drugs have 
been demonstrated to provide additional clinical benefit. Ultimately, 90% of GIST patients relapse, 
and eventually succumb, to progressing GIST. There is a still an unmet clinical need, and hence the 
search for more effective inhibitors and novel therapeutic targets continues. In this context, the work 
presented herein aimed to identify biological dependencies in GIST cells that could reveal 
vulnerabilities to be exploited for therapeutic purposes. The identification of CDC37 as an essential 
protein for GIST cells represents such a dependency, and emphasizes the importance of the HSP90 
chaperoning complex function for GIST biology. 
Inhibition of HSP90 in GIST, and other RTK-driven tumors, has been an area of active 
investigation over the last decade [Workman, 2004]. Preclinical evidence supporting this therapeutic 
approach is very strong: the activated form of KIT/PDGFRA, the oncogenic driver of GIST cells, is 
structurally unstable and highly dependent on a proficient chaperoning machinery to function 
properly. Inhibition of the HSP90 complex results in decreased KIT phosphorylation, loss of activated 
signaling intermediates, including AKT an MAPK, and severely reduces GIST cell viability and 
proliferation [Bauer et al., 2006]. Despite strong preclinical data, early clinical experience has been 
somewhat disappointing. A phase I clinical trial of retaspimycin hydrochloride (IPI-504), a 
geldanamycin-derivative HSP90 inhibitor, demonstrated activity in patients with advanced GIST who 
had progressed after treatment with imatinib and/or sunitinib, with a progression-free survival of 12 
weeks and an overall response rate of 3% [Wagner et al., 2013]. A larger scale phase III placebo-
controlled international trial was terminated early, however, due to safety concerns of hepatic toxicity 
in the IPI-504 arm, highlighting the challenges of moving from a small phase I experience to broader 
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studies, even in the same patient population [Demetri et al., 2010]. The apparent failure of HSP90 
inhibition in this early trials can be attributed to intrinsic properties of the compounds used 
(geldanamycin derivatives), to the fact that the patients enrolled were heavily pre-treated, and to the 
drug administration schedule and dosing. Trials of alternative compounds, such as ganetespib (STA-
9090), were designed to interrogate the duration of on-target activity in addition to safety profiles, 
and demonstrated that once-weekly dosing may be insufficient for optimal inhibition of KIT [Demetri 
et al., 2010]. Improvements in drug scheduling and dosing, as well as new generation compounds are 
expected to lead to clinical benefit. The results of the experiments presented herein, in which the 
HSP90 co-chaperone CDC37 scored as one of the most essential genes in an unbiased genome-wide 
screen, highlight how the HSP90 machinery is one of the most critical nodes of GIST cells biology 
and justify the sustained efforts to improve therapeutic development against HSP90. 
CDC37 targeting could provide some therapeutic advantages over direct HSP90 targeting. 
Recent estimates indicate that HSP90 inhibition alters the expression of several hundreds of cytosolic 
proteins [Samant et al., 2012; Sharma et al., 2012]. In contrast, CDC37 binds to just a fraction of 
those, by virtue of its kinase specificity [Vaughan et al., 2008; Smith and Workman, 2009; Smith et 
al., 2009]. This fact alone is likely to confer more specificity to CDC37 inhibition, and the fact that 
kinases are the main class of proteins disrupted provides selectivity of action on cancer cells, 
potentially increasing the therapeutic window. An important challenge for CDC37 targeting is the 
lack of compounds with clinical-grade pharmacologic activity. The natural product celastrol -derived 
from a plant known as Thunder of God Vine, widely utilized in traditional medicine to treat a variety 
of disorders- had been initially characterized to inhibit the HSP90:CDC37 interaction in vitro [Zhang 
et al., 2009], but a series of additional publications describing a range of seemingly unrelated effects 
[Liu et al., 2015] indicate that this compound lacks specificity, and probably acts upon multiple 
biochemical substrates in the cell. Our own results support this interpretation, since the decrease of 
GIST cell viability induced by celastrol was independent of the presence of KIT (Figure 14). 
Inhibiting the interaction between CDC37 and HSP90 would theoretically interfere with the function 
of the HSP90 complex [Taipale et al., 2012], and several protein:protein interaction inhibitors have 
been hypothesized, but the relevance of each interactor within the complex is still poorly understood. 
Furthermore, direct interaction between HSP90 and CDC37 may not be necessary for proper function 
of the complex, and other components of the complex may be able to compensate for the lack of them 
[Smith et al., 2015]. Modulation of CD37 activation, which occurs by phosphorylation of serine 13, 
may provide an additional point of pharmacologic attack on CDC37. The main regulators of 
phosphorylation at this site are CK2 and PPP5, which may be inhibited therapeutically. However, 
these kinase and phosphatase act on a large number of substrates, so their inhibition may lead to 
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undesired effects on other targets. We are actively evaluating these additional targets in the 
laboratory, and we will follow up on the most promising leads that could provide a therapeutic effect. 
There are biological and technical aspects regarding the use of shRNA libraries that deserve 
consideration. First, the level of interference of a shRNA on the target transcript is variable, 
depending on the design of the hairpin, the specific sequence, and the transcriptional and cellular 
context. As a result, the on-target knockdown efficiency of any given shRNA is variable, and to some 
extent unpredictable. Second, in addition to knocking down the intended target gene transcript by 
complementarity of its 21 nucleotide sequence, shRNAs knock down transcripts of other genes and 
produce off-target effects. Most of these are the result of the shRNAs behaving like miRNAs, by 
virtue of a shared sequence of 6-8 nucleotides (comprised within nucleotides 2-8), known as the seed 
region [Doench et al., 2003]. These seed regions allow the hairpins to bind the transcripts of 
unintended groups of genes and reduce their availability via the miRNA pathway [Jackson et al., 
2006], and have been proven to significantly contribute to the phenotype induced by the shRNAs in 
several cell contexts [Franceschini et al., 2014; Singh et al., 2015]. For these reasons, redundancy is 
introduced into shRNA libraries, and each gene is targeted by multiple shRNAs. In the case of the 
TRC library utilized here, there are 6 shRNAs per gene on average. The most recently developed 
‘ultracomplex’ libraries include 25-50 shRNAs per gene and thousands of negative control sequences, 
adding up to over 500,000 shRNAs [Kampmann et al., 2015]. Computational approaches allow to 
identify the signal produced by on target effects, and subtract or at least quantify the magnitude of 
off-target effects driven by seed sequences and interpret the data in this context [Sigoillot et al., 2012; 
Zhong et al., 2014]. Occasionally, these analyses help identify biological events driven by 
microRNAs [Schultz et al., 2011; Buehler et al., 2012]. For the results presented here, we performed 
a customized analysis with a biocomputational tool developed at the Broad Institute to identify seed 
effects in the data (this tool is designated miRkat, and will be made available to the community in 
upcoming months within the DEMETER algorithm, which estimates the relative contributions of 
hairpin-related and seed-related effects for each gene); off-target effects in our datasets were not 
statistically significant, and did not mask the signal produced by on-target effects. 
These biological and technical features of shRNAs influence the computational analyses 
performed to collapse shRNA-level information into gene-level information for large scale shRNA 
screens. The simplest approach, a rank of hairpins according to their relative enrichment and depletion 
at the end of the experiment, is prone to false positive results by over-representation of the hairpins 
with more severe off-target effects. To enrich for on-target effects, there are statistical approaches 
that consider the ranks of all the shRNAs targeting each gene, to generate an RNAi Gene Enrichment 
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Ranking (RIGER). Using a non-parametric method based on Kolmogorov-Smirnov statistics, it is 
possible to assign a score to each gene based on the depletion or enrichment of the corresponding 
shRNA set within the absolute rank, based on the comparison of two classes. This method is similar 
to the widely used gene set enrichment analysis (GSEA) and has been described and extensively 
validated in the literature [Luo et al., 2008; Barbie et al., 2009]. Empirically, it has been observed 
that ranking the genes according to the second-best-scoring hairpin in the absolute distribution 
provides a very accurate rank, which captures useful biological information in large scale genomic 
shRNA screens. This “second-best” method provides a simple mechanism to neutralize outliers, and 
has been applied successfully to screen multiple different biological systems [Cheung et al., 2011; 
Marcotte et al., 2012; Zhang et al., 2013]. We analyzed our datasets with both RIGER and the “second 
best” method, and the results at the extremes of the rank were very similar, indicating a high signal-
to-noise ratio. As the number of screens with similar platforms increases, it is becoming possible to 
analyze the performance of each reagent (shRNA) across multiple experiments, and assign them a 
“quality score” that can be used to weight the results and generate more informative ranks and hit 
lists. Novel algorithms such as ATARiS and DEMETER take into consideration the results of 
multiple experiments and provide information about the quality and performance of each reagent, 
allowing to extract more information from datasets with more noise [Shao et al., 2013]. 
 
Beyond these technical and biological considerations of the screens themselves, the most 
important analyses are those relative to the biology of the model of study. The systematic application 
of functional genomics has the potential to reveal the basic blueprint of cellular survival and 
proliferation. Moreover, these approaches can uncover genes that are exclusively essential for cancer 
cells, genes that mediate the cellular response to therapy, or those that behave as synthetic lethals 
with a given intervention, all of which are potentially useful for the development of specific 
anticancer therapies. Cumulative experience in the field has revealed several challenges inherent to 
functional genomic technologies, most of them related to off-target effects and low signal-to-noise 
ratio in some systems [Hart et al., 2014]. Ongoing efforts aim to systematically collect and compare 
the numerous datasets generated by functional genomic experiments, to build gold-standard databases 
and reference sets to provide a working framework that will maximize the output of each individual 
experiment [Hart et al., 2014]. Triangulation of functional data with structural genomic data and 
chemical screens will maximize the yield of all these approaches collectively [Jerby-Arnon et al., 
2014].  
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Important questions remain to be answered regarding GIST biology: the process of tumor 
initiation, oncogenic progression, the degree and clinical significance of tumor heterogeneity, 
histopathological correlation with molecular characteristics, the biology of rare histological subtypes, 
and precise prognostication, to name a few, all can provide important clues to further improvement 
patient management. Our laboratory is actively working on all these questions, utilizing state-of-the-
art technologies and experimental approaches that are generating an unprecedented wealth of data. It 
is not an overstatement to affirm that our understanding of GIST biology, tumor heterogeneity, and 
mechanisms of drug resistance is improving every week. It is fair to expect that in the next few years 
there will be substantial advances in the treatment of GIST, which will maximize long-term disease 
control and hopefully improve GIST patients’ outcomes. 
  
44/92 
 
  
 45/92 
Conclusiones 
 
1. En el marco de este trabajo hemos desarrollado con éxito una plataforma de genómica 
funcional para el estudio genético sistemático de modelos celulares de sarcoma. 
2. Con esta plataforma genómica es posible analizar individualmente la función de más de 
12,000 genes, utilizando librerías de RNA interferente que permiten silenciar cada gen de 
manera específica, en un contexto celular fisiológico. 
3. Aplicando esta tecnología funcional de alto rendimiento hemos realizado experimentos de 
pérdida de función a escala genómica en células de tumor del estroma gastrointestinal (GIST). 
4. La proteína CDC37 es una nueva diana terapéutica en GIST, esencial para la biología tumoral, 
identificada mediante experimentos de screening a escala genómica. 
5. CDC37 interacciona con la oncoproteína KIT en las células de GIST, y es un factor 
indispensable para la función oncogénica de KIT. 
6. Experimentos de validación preclínica demuestran que la inhibición de KIT a través de 
CDC37 puede realizarse de forma selectiva y eficaz en GIST. 
7. La inhibición de KIT mediante CDC37 presenta ventajas en comparación con la inhibición 
de HSP90, como son la inhibición prolongada de la expresión de KIT y la reducción de la 
población de proteínas afectadas a solo una fracción de las proteínas “cliente” de HSP90. 
8. La inhibición selectiva de CDC37 es una aproximación terapéutica efectiva y menos tóxica 
que la inhibición de HSP90 en pacientes con GIST. 
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